SERPASIL-ESIDRIX #1
Clinical safety rating
cautionComprehensive clinical and safety monograph for SERPASIL-ESIDRIX #1 (SERPASIL-ESIDRIX #1).
Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
| Metabolism | Reserpine: extensive hepatic metabolism; Hydrochlorothiazide: not significantly metabolized, excreted unchanged in urine. |
| Excretion | Reserpine: renal (30% as metabolites, <1% unchanged), fecal (60% as metabolites). Hydrochlorothiazide: renal (>95% unchanged). |
| Half-life | Reserpine: 50-100 hours (terminal); clinical effects persist due to irreversible adrenergic neuron blockade. Hydrochlorothiazide: 6-15 hours (terminal). |
| Protein binding | Reserpine: 96% bound to albumin. Hydrochlorothiazide: 68% bound to plasma proteins. |
| Volume of Distribution | Reserpine: 6-8 L/kg (extensive tissue binding, especially adrenergic neurons). Hydrochlorothiazide: 0.8-1.0 L/kg (enters erythrocytes). |
| Bioavailability | Reserpine: oral 30-50% (presystemic metabolism). Hydrochlorothiazide: oral 65-75%. |
| Onset of Action | Reserpine: oral 3-6 days; IM 1-3 hours. Hydrochlorothiazide: oral 2 hours; diuresis peaks at 4-6 hours. |
| Duration of Action | Reserpine: oral 1-6 weeks (cumulative effect); antihypertensive effect persists after discontinuation. Hydrochlorothiazide: oral 6-12 hours. |
| Molecular Weight | Reserpine: 608.69 Da; Hydrochlorothiazide: 297.74 Da |
1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-50 mL/min: reduce dose by 50% or extend interval. eGFR <30 mL/min: contraindicated due to thiazide ineffectiveness. |
| Liver impairment | Child-Pugh A: standard dosing. Child-Pugh B: reduce reserpine dose by 50%. Child-Pugh C: avoid use. |
| Pediatric use | Reserpine: 0.005-0.02 mg/kg/day orally in 1-2 divided doses. Hydrochlorothiazide: 1-2 mg/kg/day orally in 2 divided doses. Adjust per response. |
| Geriatric use | Start at half the standard dose (0.5 tablet orally daily). Titrate slowly due to increased sensitivity to hypotension, CNS depression, and electrolyte disturbances. |
| 1st trimester | Reserpine is contraindicated in first trimester due to risk of fetal bradycardia, respiratory depression, and potential teratogenic effects. Hydrochlorothiazide crosses placenta; may cause electrolyte disturbances and volume depletion. Use only if benefit outweighs risk. |
| 2nd trimester | Avoid use. Reserpine may cause fetal bradycardia and nasal congestion. Hydrochlorothiazide may reduce placental perfusion. Alternative antihypertensives preferred. |
| 3rd trimester | Avoid near term. Reserpine can cause neonatal bradycardia, hypotonia, and nasal congestion. Hydrochlorothiazide may cause neonatal electrolyte disturbances, thrombocytopenia, and hyperbilirubinemia. |
Clinical note
Comprehensive clinical and safety monograph for SERPASIL-ESIDRIX #1 (SERPASIL-ESIDRIX #1).
| Placental transfer | Both reserpine and hydrochlorothiazide cross the placenta. Reserpine achieves significant fetal concentrations; hydrochlorothiazide crosses readily and can cause fetal/neonatal electrolyte disturbances. |
| Breastfeeding | Reserpine is excreted into breast milk and may cause adverse effects in the nursing infant, including nasal congestion, respiratory depression, and galactorrhea. Hydrochlorothiazide is excreted in low amounts but may suppress lactation. Not recommended during breastfeeding. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: Reserpine crosses placenta; associated with increased risk of congenital malformations (neural tube defects, cardiovascular anomalies) based on animal data and limited human reports. Second/third trimester: Use associated with fetal bradycardia, hypotonia, hypothermia, respiratory depression, and meconium ileus due to catecholamine depletion; risk of neonatal hypotension and poor feeding. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of depression. For fetus/neonate: serial ultrasound for growth restriction, amniotic fluid index, fetal heart rate monitoring; postnatal assess for bradycardia, hypotonia, respiratory distress, and electrolyte imbalances (hyponatremia, hypokalemia from thiazide). |
| Fertility Effects | Reserpine may impair fertility via suppression of hypothalamic-pituitary axis causing prolactin elevation and menstrual irregularities; hydrochlorothiazide may cause transient erectile dysfunction but no direct effect on fertility. Overall, potential for reversible reduced fertility. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to reserpine or hydrochlorothiazideHistory of mental depression (especially with suicidal tendencies)Active peptic ulcer diseaseUlcerative colitisElectroconvulsive therapy (within 7 days)Inability to tolerate beta-blockade (reserpine component)Anuria or severe renal impairmentSulfonamide allergy (hydrochlorothiazide cross-sensitivity)Pregnancy (first trimester and near term)Breastfeeding
| Precautions | May cause mental depression, including suicidal risk, Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia), Orthostatic hypotension, Increased risk of arrhythmias with digoxin, May exacerbate systemic lupus erythematosus, May activate peptic ulcer, Monitor renal function and electrolytes |
| Food/Dietary | Avoid high-potassium foods (bananas, oranges, leafy greens) if taking potassium-sparing agents, but this combination does not include them. Limit sodium intake to enhance antihypertensive effect. Avoid grapefruit juice as it may increase reserpine absorption. Maintain adequate fluid intake but avoid excessive water intake due to risk of hyponatremia. |
| Clinical Pearls | Serpasil-Esidrix #1 combines reserpine (a Rauwolfia alkaloid) and hydrochlorothiazide (a thiazide diuretic). Reserpine depletes catecholamines and serotonin, causing gradual BP reduction. Onset of antihypertensive effect is delayed (2-3 weeks). Monitor for depression, nasal congestion, and extrapyramidal effects. Hydrochlorothiazide may cause hypokalemia, hyponatremia, and hyperglycemia. Avoid use in patients with history of depression, peptic ulcer, or electrolyte imbalances. Combination product offers convenience but fixed dosing limits titration. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination. · Do not stop abruptly; sudden withdrawal may cause rapid blood pressure rise. · Report symptoms of depression, mood changes, or unusual tiredness promptly. · Avoid alcohol, which may increase dizziness and drowsiness. · Use sun protection; this drug increases photosensitivity risk. · Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat. · Weigh yourself regularly and report rapid weight gain or swelling. · Avoid potassium supplements or salt substitutes unless directed by your doctor. |
Loading safety data…